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Abstract
Type 2 diabetes (T2DM) is a multifactorial disease related to both environmental and genetic factors. While environmental 
factors leading to the development for T2DM are well established, the majority of factors responsible for the genetic 
background of the disease remain unknown. The aim of this study was to test whether a rare variant within the HNF4A gene, 
Thr130Ile (rs1800961), may influence the development of clinical course of T1DM or T2DM subjects. The analysis included 
574 patients with T2DM, 207 T1DM individuals and 284 healthy controls. All subjects were genotyped for the Thr130Ile 
polymorphism in HNF4A. For T2DM, no differences were found in allele frequencies between cases and controls. The 
percentage of CT genotype in these groups were 5.7% (33 patients) and 5.6% (16 healthy controls), respectively (p=0.89). 
For T1DM, the allele frequency was not statistically different from T2DM or control subjects. In conclusion, no association 
was found between rare variant Thr130Ile of the HNF4A gene and the development of either T2DM nor T1DM in the Polish 
population.
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INTRODUCTION
Type 2 diabetes (T2DM) is a multifactorial disease 
related to both environmental and genetic factors. While 
environmental factors leading to the development for T2DM 
are well established, the majority of factors responsible for 
the genetic background of the disease remain unknown. In 
the last few years, research concerning genetic factors leading 
to the development of T2DM has been mainly related to 
the common single nucleotide variants (SNVs). However, 
these mutations only account for a small fraction of the 
total genetic susceptibilities to T2DM [1]. The potential 
cause(s) of the missing heritability in SNV-oriented 
genome-wide association studies (GWAS) is unclear, but 
possible contributors may include rare gene variants [1]. 
The hepatocyte nuclear factor 4-α (HNF4A) gene codes 
for the transcription factor, is responsible for regulating 
gene transcription in pancreatic beta cells, in addition to its 
primary role in regulation of hepatic genes [2]. Mutations 
in HNF4A may cause maturity onset diabetes of the young 
(MODY) form of diabetes [2]. HNF4A may be considered an 
interesting candidate gene for T1DM, since HNF4A protein 
regulates endoplasmic reticulum stress-induced apoptosis 
in pancreatic β-cells [3]. The role of common variants of 
HNF4A in modifying the risk of development of T2DM 
remains unclear [1, 4]. However, it has been shown that rare 
variants within HNF4A may contribute to the development 
of T2DM [5].
OBJECTIVE
The aim of this study was to test whether a rare variant within 
the HNF4A gene, Thr130Ile (rs1800961), may influence the 
development of clinical course of T1DM or T2DM subjects.
MATERIALS AND METHOD
The study included 574 patients with T2DM, 207 T1DM 
individuals and 284 healthy controls. All patients were 
residents of southern Poland. DNA of the examined 
individuals was isolated from the lymphocytes of peripheral 
blood using QIAamp DNA Mini Kit (Qiagen). All subjects 
were genotyped for the Thr130Ile polymorphism in HNF4A 
by Taqman allelic discrimination assays and sequencing 
(TaqMan® Gene Expression Assays, Thermo Fisher Scientific 
Inc., Carlsbad, CA, USA).
All study subjects gave informed consent. The 
project was approved by the local Ethics Committee 
(KBET/292/B/2011) and was conducted in accordance with 
the Declaration of Helsinki. For statistical analysis, tests 
for differences between the two groups was performed with 
Student t-test or Mann–Whitney U-test. For categorical 
variables, either chi-square test or Fisher exact test were used 
where appropriate. Differences in patient age and time span 
from age of diagnosis to the age when insulin therapy was 
necessary between genotypes were assessed with Kruskal–
Wallis test.
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RESULTS
Clinical characteristics of the studied population divided 
into genotypes is summarized in Tables 1–3. For T2DM, no 
differences were found in allele frequencies between cases 
and controls. The percentages of CT genotype in these 
groups were 5.7% (33 patients) and 5.6% (16 healthy controls), 
respectively (p=0.89). No TT genotype was found in either 
group. Among patients with T2DM, no association was 
found between genotype and age of diagnosis (p=0.60), nor 
between genotype and time span from age of diagnosis to 
the age when insulin therapy was necessary (p=0.75) (Tab. 4).
For T1DM, the allele frequency was not statistically different 
from T2DM or control subjects (CT genotype frequency: 
2.4% (5 patients), p = 0.1), there was also no association 
between genotype and the age of diagnosis (p=0.89) (Tab.5).
DISCUSSION
The study was motivated by the results of two meta-analysies 
concerning the role of HNF4A Thr130Ile variant in the 
development of T2DM. Jafar-Mohammadi et al. [6] found 
the more common Thr130Ile variant to be associated 
with T2DM in a meta-analysis of 14,279 cases and 26,835 
controls. Although the p-values for association of Thr130Ile 
with T2DM in this study did not reach the threshold of 
significance, the odds ratios were in the same direction and 
of a similar magnitude for the additive model (OR 1.22; 95% 
CI: 0.87–1.71). Sookoian et al. [7] analyzed studies containing 
Thr130Ile based on 15,020 T2DM cases and 15,010 controls. 
They found no evidence of association of the major allele 
at this variant under a fixed model (p=0.160), although 
nominal significance was detected under a random model 
(p=0.045; OR=0.770 (95% CI: 0.595–0.995). Hellwege at al. 
[8] examined 1,270 T2DM cases and 1,017 controls and 
found no difference concerning HNF4A Thr130Ile variant 
between cases and controls, but this study analyzed a selected 
population of European- Americans. In the current study, 
similar analysis concerned the Polish population, but the 
results were negative, in line with the report by Hellwege. 
The authors, for the first time, have analyzed the relationship 
between HNF4A Thr130Ile variant and the development of 
T1DM, founding, however, no association. Thus, the role 
of rare variants in the development of common forms of 
diabetes remain to be established [9].
CONCLUSIONS
No association was found between rare variant Thr130Ile of 
the HNF4A gene and the development of either T2DM nor 
T1DM in the Polish population. The variant does not seem 
the affect age of diagnosis or the need for insulin therapy in 
T2DM patients, nor is it associated with the age of diagnosis 
in T1DM patients.
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Table 1. Clinical characteristics of patients with type 2 diabetes divided 
into genotypes
T2DM
CC CT
N 541 33
Male 276 17
Female 265 16
Age+ 58.4 ± 10.2 58.8 ± 10.2
Age at diagnosis+ 48.4 ± 9.8 47.3 ± 9.8
Duration of illness+ 10.1 ± 7.7 12.2 ± 6.9
BMI
<25 kg/m² 56 (10.9 %) 1 (3.1%)
25-29 kg/m² 158 (30.6%) 14 (43.8%)
>30 kg/m² 302 (58.5%) 17 (53.1%)
Insulin
 YES 310 (60.0%) 15 (50.0%)
 NO 207 (40.0%) 15 (50.0%)
Mean values ± SD;  + – years
Table 5. Age of diagnosis vs genotype in T1DM patients
CT CC p-value OR (95 %CI)
% of genotypes T1DM 5 (2.4%) 202 (97.6%) 0.1 1.02 (0.55–1.89)
Control 16 (5.6%) 268 (94.4%)
Age at diagnosis 16.8 ± 7.7 17.8 ± 8.1 0.89
Table 2. Clinical characteristics of patients with type 2 diabetes divided 
into genotypes
T1DM
CC CT
N 202 5
Male 22 2
Female 180 3
Age+ 29.2 ± 5.6 30.2 ± 6.5
Age at diagnosis + 17.8 ± 8.1 16.8 ± 7.7
Duration of illness + 11.3 ± 7.4 10.6 ± 12.4%
Mean values ± SD;  + – years
Table 3. Clinical characteristics of the control group divided into 
genotypes
CONTROLS
CC CT
N 268 16
Male 106 7
Female 162 9
Age+ 48.6 ± 14.7 43.6 ± 13.3
Mean values ± SD;  + – years
Table 4. Age of diagnosis vs genotype in T2DM patients
CT CC p-value OR (95 %CI)
% of genotypes T2DM 33 (5.7%) 541 (94.2%) 0.89 1.02 (0.55-1.89)
Control 16 (5.6%) 268 (94.4%)
Age at diagnosis 12.2 ± 6.9 48.4 ± 9.8 0.60
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